Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for IVTA-resistant diabetic macular oedema
ACTRN12611001210965Phase 3Completed
- Sponsor
- University of Sydney
- Start
- Jun 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in diabetic macular edema (DME), sponsored by University of Sydney. Started Jun 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ACTRN12611001210965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001210965.